chr6-73621864-A-C
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The ENST00000355773.6(SLC17A5):āc.918T>Gā(p.Tyr306Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00007 in 1,613,600 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (ā ā ). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
ENST00000355773.6 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SLC17A5 | NM_012434.5 | c.918T>G | p.Tyr306Ter | stop_gained | 7/11 | ENST00000355773.6 | NP_036566.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SLC17A5 | ENST00000355773.6 | c.918T>G | p.Tyr306Ter | stop_gained | 7/11 | 1 | NM_012434.5 | ENSP00000348019 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000138 AC: 21AN: 152248Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000835 AC: 21AN: 251364Hom.: 0 AF XY: 0.0000442 AC XY: 6AN XY: 135866
GnomAD4 exome AF: 0.0000630 AC: 92AN: 1461234Hom.: 0 Cov.: 30 AF XY: 0.0000481 AC XY: 35AN XY: 726962
GnomAD4 genome AF: 0.000138 AC: 21AN: 152366Hom.: 0 Cov.: 33 AF XY: 0.000134 AC XY: 10AN XY: 74504
ClinVar
Submissions by phenotype
Salla disease Pathogenic:6
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Sep 05, 2021 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | This sequence change creates a premature translational stop signal (p.Tyr306*) in the SLC17A5 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SLC17A5 are known to be pathogenic (PMID: 10581036, 10947946, 15172001). This variant is present in population databases (rs201284672, gnomAD 0.04%). This premature translational stop signal has been observed in individual(s) with sialic acid storage disease (PMID: 10947946, 24993898). ClinVar contains an entry for this variant (Variation ID: 440272). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 25, 2018 | Variant summary: SLC17A5 c.918T>G (p.Tyr306X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 7.9e-05 in 277192 control chromosomes. This frequency is not higher than expected for a pathogenic variant in SLC17A5 causing Sialic Acid Storage Disorder (7.9e-05 vs 0.0024), allowing no conclusion about variant significance. c.918T>G has been reported in the literature in several individuals affected with Sialic Acid Storage Disorder, including a homozygous fetus with significantly elevated levels of free sialic acid (Froissart_2005). These data indicate that the variant is likely to be associated with disease. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 18, 2024 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Counsyl | Oct 23, 2017 | - - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Mar 01, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Sep 01, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Nov 04, 2021 | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 25525159, 24993898, 10947946, 15805149, 24767253, 32071839, 34440436, 31589614) - |
Sialic acid storage disease, severe infantile type Pathogenic:2
Pathogenic, criteria provided, single submitter | research | Bruce Lefroy Centre, Murdoch Childrens Research Institute | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Knight Diagnostic Laboratories, Oregon Health and Sciences University | Apr 08, 2018 | - - |
not specified Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Sep 14, 2016 | - - |
Sialic acid storage disease, severe infantile type;C1096903:Salla disease Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at